Physician profile
Ashley Baldree
NPI 1225667066
$5,094.94
in general payments reported to CMS, 2019-2025
21 companies · $4,216 in 2025
The $4,216 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $879 · 2025: $4,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,949 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,948.96 |
| Education | $145.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $735.49 | 2025 | Daxxify, Daxi |
| Abbvie INC. | $541.44 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $506.39 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $482.56 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $477.07 | 2024-2025 | |
| Genzyme Corporation | $362.85 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $232.68 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $214.60 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $204.99 | 2024-2025 | Dupixent |
| Ucb, INC. | $198.08 | 2025 | Bimzelx |
| Pfizer INC. | $194.20 | 2024-2025 | |
| Leo Pharma INC. | $167.52 | 2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $154.79 | 2025 | Ebglyss, Taltz |
| Amgen INC. | $119.66 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $109.41 | 2024-2025 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $109.19 | 2025 | Nemluvio |
| Organon LLC | $102.68 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Dermavant Sciences, INC. | $50.40 | 2024 | Vtama |
| Botanix Sb INC | $32.12 | 2025 | Sofdra |
| Medline Industries LP | $18.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Baldree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.